S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
OTCMKTS:FZMD

Fuse Medical Stock Competitors

$0.20
-0.10 (-33.30%)
(As of 01/18/2022 03:47 PM ET)
Add
Compare
Today's Range
$0.15
$0.39
50-Day Range
$0.28
$0.69
52-Week Range
$0.08
$1.90
Volume
22,460 shs
Average Volume
27,910 shs
Market Capitalization
$14.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Fuse Medical (OTCMKTS:FZMD) Vs. ELDN, ECOR, MYO, FOXW, SNPX, EYES, COCP, BPTS, BMRA, and CYCN

Should you be buying Fuse Medical stock or one of its competitors? The main competitors of Fuse Medical include Eledon Pharmaceuticals (ELDN), electroCore (ECOR), Myomo (MYO), FoxWayne Enterprises Acquisition (FOXW), Synaptogenix (SNPX), Second Sight Medical Products (EYES), Cocrystal Pharma (COCP), Biophytis (BPTS), Biomerica (BMRA), and Cyclerion Therapeutics (CYCN). These companies are all part of the "medical & hospital equipment" industry.These companies are all part of the "medical & hospital equipment" industry.These companies are all part of the "medical" sector.

Fuse Medical vs.

Fuse Medical (OTCMKTS:FZMD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Fuse Medical has higher revenue and earnings than electroCore. Fuse Medical is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fuse Medical$21.40 million0.68-$1.43 million-$0.02-10.01
electroCore$3.50 million16.65-$23.51 million-$0.37-2.23

In the previous week, electroCore had 8 more articles in the media than Fuse Medical. MarketBeat recorded 9 mentions for electroCore and 1 mentions for Fuse Medical. electroCore's average media sentiment score of 0.14 beat Fuse Medical's score of 0.00 indicating that electroCore is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fuse Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
electroCore
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

electroCore received 103 more outperform votes than Fuse Medical when rated by MarketBeat users. However, 66.67% of users gave Fuse Medical an outperform vote while only 60.71% of users gave electroCore an outperform vote.

CompanyUnderperformOutperform
Fuse MedicalOutperform Votes
50
66.67%
Underperform Votes
25
33.33%
electroCoreOutperform Votes
153
60.71%
Underperform Votes
99
39.29%

Fuse Medical has a net margin of -4.88% compared to electroCore's net margin of -380.36%. Fuse Medical's return on equity of 0.00% beat electroCore's return on equity.

Company Net Margins Return on Equity Return on Assets
Fuse Medical -4.88% N/A -5.87%
electroCore -380.36% -69.00% -55.55%

20.0% of electroCore shares are owned by institutional investors. 92.9% of Fuse Medical shares are owned by company insiders. Comparatively, 13.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

electroCore has a consensus price target of $2.31, indicating a potential upside of 180.27%. Given electroCore's higher probable upside, analysts plainly believe electroCore is more favorable than Fuse Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fuse Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
electroCore
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Fuse Medical and electroCore tied by winning 8 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FZMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Fuse Medical (OTCMKTS:FZMD) vs. Its Competitors

TypeFuse MedicalMedical & hospital equipment IndustryMedical SectorOTCMKTS Exchange
Market Cap$14.65M$7.58B$4.71B$7.45B
Dividend YieldN/A1.39%2.00%6.72%
P/E Ratio-10.0116.5117.382.26
Price / Sales0.681.846,319.39376.21
Price / CashN/A16.3334.0424.02
Price / Book-6.673.427.875.67
Net Income-$1.43M$216.37M$98.22M$427.65M
7 Day PerformanceN/A-10.33%-4.14%0.83%
1 Month Performance-59.08%-7.96%-7.34%125.05%
1 Year PerformanceN/A11.94%-16.53%74.62%

Fuse Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
2.3031 of 5 stars
$4.09
-8.3%
$27.67
-576.4%
-69.8%$58.52MN/A0.0010Gap Down
ECOR
electroCore
2.1248 of 5 stars
$0.82
-7.7%
$2.31
-180.3%
-57.0%$58.27M$3.50M-2.2345
MYO
Myomo
2.0914 of 5 stars
$8.43
-0.9%
$25.50
-202.5%
N/A$57.83M$7.58M-4.7963Analyst Downgrade
Short Interest ↓
FOXW
FoxWayne Enterprises Acquisition
0.3333 of 5 stars
$9.96
-0.1%
N/AN/A$57.77MN/A0.001Short Interest ↑
Negative News
SNPX
Synaptogenix
0 of 5 stars
$8.65
-3.6%
N/AN/A$57.73MN/A0.004Gap Up
EYES
Second Sight Medical Products
1.2131 of 5 stars
$1.46
-5.5%
N/A-9.9%$57.54M$3.38M0.0012News Coverage
High Trading Volume
COCP
Cocrystal Pharma
1.7581 of 5 stars
$0.58
-2.8%
$4.50
-671.1%
-60.3%$56.88M$2.01M-4.4913Short Interest ↑
BPTS
Biophytis
1 of 5 stars
$4.70
-4.3%
N/AN/A$56.76MN/A0.002,020Gap Down
BMRA
Biomerica
1.8981 of 5 stars
$4.51
-2.7%
$13.00
-188.2%
-23.0%$56.43M$7.20M-9.4045Earnings Report
Short Interest ↑
Analyst Revision
Gap Up
CYCN
Cyclerion Therapeutics
2.0231 of 5 stars
$1.30
-6.9%
$11.67
-797.4%
-56.8%$56.31M$2.30M0.0051Short Interest ↓
Positive News
LUMO
Lumos Pharma
2.1583 of 5 stars
$6.73
-6.7%
$28.00
-316.0%
-66.1%$56.24M$170K-2.0529Short Interest ↓
Gap Down
DMAC
DiaMedica Therapeutics
1.6931 of 5 stars
$2.97
-13.8%
$20.50
-590.2%
-66.3%$55.79MN/A-3.8611Short Interest ↓
Positive News
Gap Down
POAI
Predictive Oncology
1.6781 of 5 stars
$0.85
-4.8%
$4.00
-370.6%
-10.9%$55.74M$1.25M-0.9323Negative News
GANX
Gain Therapeutics
1.6248 of 5 stars
$4.67
-0.2%
$27.00
-478.2%
N/A$55.48M$30K0.0016Short Interest ↓
News Coverage
Gap Up
CPIX
Cumberland Pharmaceuticals
1.4665 of 5 stars
$3.74
-6.7%
N/A+23.1%$55.39M$37.44M-93.5090Short Interest ↓
Positive News
Gap Down
LTUS
Lotus Pharmaceuticals
0 of 5 stars
$0.02
-0.0%
N/A+23.3%$54.47MN/A0.00533News Coverage
HCTI
Healthcare Triangle
0 of 5 stars
$1.57
-9.6%
N/AN/A$54.47M$31.34M0.002,021Gap Down
High Trading Volume
XTNT
Xtant Medical
1.2931 of 5 stars
$0.63
-3.2%
N/AN/A$54.45M$53.34M-15.70110Short Interest ↑
ISR
Isoray
1.9098 of 5 stars
$0.38
-1.3%
$2.12
-454.2%
N/A$54.20M$10.05M-7.6453Short Interest ↓
OGEN
Oragenics
0.9064 of 5 stars
$0.46
-1.6%
N/AN/A$53.87MN/A-2.727Short Interest ↑
APRE
Aprea Therapeutics
1.7832 of 5 stars
$2.50
-5.6%
$4.00
-60.0%
-48.7%$53.66MN/A-1.1817Short Interest ↓
Gap Down
BIOC
Biocept
1.2964 of 5 stars
$3.17
-4.1%
N/A-38.4%$53.39M$27.46M14.41107
INTI
Inhibitor Therapeutics
0 of 5 stars
$0.14
-0.0%
N/AN/A$52.99MN/A0.002
HOOK
Hookipa Pharma
2.1898 of 5 stars
$2.02
-1.5%
$11.80
-484.2%
-81.5%$52.80M$19.58M-0.9556News Coverage
Gap Up
LYRA
Lyra Therapeutics
1.3565 of 5 stars
$4.05
-2.5%
N/A-63.9%$52.67MN/A-1.4738
AST
Asterias Biotherapeutics
0.9064 of 5 stars
N/AN/AN/A$52.32MN/A0.00N/ANews Coverage
Gap Down
HPPI
HedgePath Pharmaceuticals
0.7998 of 5 stars
$0.14
-0.0%
N/A+0.0%$52.09MN/A0.002
IGXT
IntelGenx Technologies
1.0464 of 5 stars
$0.35
-1.4%
N/A+28.4%$51.94M$1.54M-4.934Gap Up
FRLN
Freeline Therapeutics
1.9278 of 5 stars
$1.45
-1.4%
$16.88
-1,063.8%
-91.7%$51.93MN/A0.002,020Short Interest ↑
News Coverage
CMPI
Checkmate Pharmaceuticals
2.0032 of 5 stars
$2.40
-5.8%
$18.33
-663.9%
-80.8%$51.91MN/A0.0025Short Interest ↑
News Coverage
Gap Down
VIRI
Virios Therapeutics
2.2 of 5 stars
$6.21
-2.4%
$12.00
-93.2%
-22.1%$51.73MN/A-2.37368Gap Up
ADIL
Adial Pharmaceuticals
2.2648 of 5 stars
$2.49
-5.2%
$11.00
-341.8%
+36.5%$51.71MN/A-2.472,018
NTRB
Nutriband
0.9649 of 5 stars
$6.65
-2.6%
N/A-48.2%$51.70M$940K-8.424Gap Down
SSKN
STRATA Skin Sciences
1.3381 of 5 stars
$1.50
-1.3%
N/A-9.8%$51.55M$23.09M-21.43109Short Interest ↓
Positive News
NEPH
Nephros
1.7048 of 5 stars
$5.00
-5.0%
$13.83
-176.7%
-31.6%$51.17M$8.56M-13.1627Positive News
Gap Up
BJDX
Bluejay Diagnostics
1.7 of 5 stars
$2.58
-3.1%
$10.00
-287.6%
N/A$50.32MN/A0.002,021Gap Down
IGC
India Globalization Capital
0.8531 of 5 stars
$0.98
-1.1%
N/AN/A$50.25M$900K-3.7950News Coverage
Gap Down
DCTH
Delcath Systems
2.2048 of 5 stars
$6.81
-3.1%
$24.33
-257.3%
-56.3%$50.09M$1.16M-1.9236News Coverage
Gap Down
ISPC
iSpecimen
2.0333 of 5 stars
$5.67
-10.2%
$20.00
-252.7%
N/A$49.49M$8.18M0.0037Gap Down
MBRX
Moleculin Biotech
0.9331 of 5 stars
$1.73
-1.2%
N/A-70.6%$49.44MN/A0.0013Positive News
MITO
Stealth BioTherapeutics
1.5265 of 5 stars
$0.85
-5.9%
$3.50
-311.8%
-40.0%$48.95M$21.09M-2.072,020Short Interest ↑
Gap Down
YBGJ
Yubo International Biotech
0.3333 of 5 stars
$0.41
-0.0%
N/AN/A$48.69MN/A0.0020Short Interest ↑
IMRA
IMARA
2.3115 of 5 stars
$1.85
-4.9%
$18.67
-909.0%
-85.9%$48.61MN/A-0.6227Short Interest ↓
PTPI
Petros Pharmaceuticals
0.6667 of 5 stars
$2.32
-12.9%
N/AN/A$47.99M$9.56M0.0027Short Interest ↓
Gap Down
MDVL
MedAvail
1.8282 of 5 stars
$1.46
-4.1%
$8.75
-499.3%
-89.9%$47.96M$13.97M-0.882,018Positive News
Gap Up
KERN
Akerna
2.2833 of 5 stars
$1.56
-3.8%
$6.63
-324.7%
-74.4%$47.95M$12.57M-1.24144
CVALF
Covalon Technologies
0.25 of 5 stars
$1.85
-0.0%
N/AN/A$47.91M$15.54M2.61N/A
AIKI
AIkido Pharma
1.7048 of 5 stars
$0.53
-0.0%
$2.00
-275.2%
-51.1%$47.78M$10K-13.325Short Interest ↑
SRZN
Surrozen
1.825 of 5 stars
$4.00
-16.0%
$19.50
-387.5%
N/A$47.74MN/A0.002,021
ADXN
Addex Therapeutics
1.6515 of 5 stars
$5.81
-2.8%
$28.00
-381.9%
-44.2%$47.71M$4.14M-2.2827Gap Up
This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.